Drug Landscape ›
GnRH antagonist ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 12
Most-reported reactions
Ectopic Pregnancy — 2 reports (16.67%) Ovarian Hyperstimulation Syndrome — 2 reports (16.67%) Abdominal Pain — 1 report (8.33%) Abortion Missed — 1 report (8.33%) Abortion Spontaneous — 1 report (8.33%) Acute Respiratory Failure — 1 report (8.33%) Ascites — 1 report (8.33%) Blighted Ovum — 1 report (8.33%) Blood Pressure Systolic Inspiratory Decreased — 1 report (8.33%) Cardiac Tamponade — 1 report (8.33%)
Source database →
GnRH antagonist in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is GnRH antagonist approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for GnRH antagonist in United States?
Merck KGaA, Darmstadt, Germany is the originator. The local marketing authorisation holder may differ — check the official source linked above.